PMC9539819_01
Craniocerebral magnetic resonance imaging of the brain showed: (A, B) Baseline: craniocerebral lesion before treatment. (C, D) Two months: after brain radiotherapy combined with osimertinib. (E, F) Seven months: after the use of erlotinib combined with capmatinib.
fonc-12-954026-g001.jpg
PMC9539819_01_fonc-12-954026-g001.jpg
f1
Brain magnetic resonance imaging (MRI) showed space-occupying lesions in the right parietal lobe (Figures 1A, B). One month later, the patient's headache was significantly relieved after brain radiotherapy (Figures 1C, D) and the ECOG PS of the patient decreased to 1. The last follow-up was in February 2022, when the patient remained on the treatment, with a PFS of 19 months and counting (Figures 1E, F).
Computed tomography scans of the chest showed the following: (A, B) Baseline: lesion in the left lung before treatment. (C, D) One month after the use of osimertinib. (E, F) Thirteen months after the use of erlotinib combined with capmatinib.
fonc-12-954026-g002.jpg
PMC9539819_01_fonc-12-954026-g002.jpg
f2
Further evaluation with computed tomography (CT) of the chest and whole-body bone scans revealed a lesion in the left lung (Figures 2A, B) and iliac bone metastasis. In September 2021, chest CT still showed a PR (Figures 2E, F) after 13 months of this treatment.